Comment on "Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study" Response

被引：0
|
作者：
Nassar, Amin H. [1 ]
Kim, So Yeon [1 ]
Adib, Elio [2 ]
Naqash, Abdul Rafeh [3 ]
Goldberg, Sarah B. [1 ]
机构：
[1] Yale Sch Med, Dept Med, Med Oncol, 333 Cedar St, New Haven, CT 06510 USA
[2] Dana Farber Canc Inst, Boston, MA USA
[3] Oklahoma Univ, Stephenson Canc Ctr, Div Med Oncol, Oklahoma City, OK USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2025年 / 20卷 / 01期
关键词：
D O I：
10.1016/j.jtho.2024.10.011
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：e2 / e3
页数：2
相关论文
共 20 条
  • [1] Comment on "Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study"
    Huang, Xiaowei
    Gu, Xian
    Xu, Zhenye
    JOURNAL OF THORACIC ONCOLOGY, 2025, 20 (01) : e1 - e2
  • [2] Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study
    Nassar, Amin H.
    Kim, So Yeon
    Aredo, Jacqueline, V
    Feng, Jamie
    Shepherd, Frances
    Xu, Chao
    Kaldas, David
    Gray, Jhanelle E.
    Dilling, Thomas J.
    Neal, Joel W.
    Wakelee, Heather A.
    Liu, Yufei
    Lin, Steven H.
    Abuali, Tariq
    Amini, Arya
    Nie, Yunan
    Patil, Tejas
    Lobachov, Anastasiya
    Bar, Jair
    Fitzgerald, Bailey
    Fujiwara, Yu
    Marron, Thomas U.
    Thummalapalli, Rohit
    Yu, Helena
    Owen, Dwight H.
    Sharp, John
    Farid, Saira
    Rocha, Pedro
    Arriola, Edurne
    'Aiello, Angelica
    Cheng, Haiying
    Whitaker, Ryan
    Parikh, Kaushal
    Ashara, Yash
    Chen, Luxi
    Sankar, Kamya
    Harris, Jeremy P.
    Nagasaka, Misako
    Ayanambakkam, Adanma
    Velazquez, Ana I.
    Ragavan, Meera
    Lin, Jessica J.
    Piotrowska, Zo fia
    Wilgucki, Molly
    Reuss, Joshua
    Luders, Heike
    Grohe, Christian
    Espinar, Javier Baena
    Feiner, Ella
    Punekar, Salman R.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (06) : 928 - 940
  • [3] Comment on "Consolidation Osimertinib Versus Durvalumab following Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC "
    Chen, Ching-Yi
    Wang, Guo-Sheng
    Wei, James Cheng-Chung
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (05) : e6 - e7
  • [4] Osimertinib Versus Durvalumab Versus Observation After Chemoradiation in Unresectable EGFR-Mutant NSCLC
    Zhao, Binghao
    Yao, Longping
    Ma, Wenbin
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (05)
  • [5] Durvalumab Consolidation Should Be the Standard Therapy in Stage III EGFR-Mutant NSCLC After Chemoradiation
    Morgensztern, Daniel
    Govindan, Ramaswamy
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (12) : 1999 - 2001
  • [6] EGFR tyrosine kinase inhibitors (TKIs) versus durvalumab (durva) following concurrent chemoradiation (CRT) in unresectable EGFR-mutant non-small-cell lung cancer (NSCLC)
    Nassar, Amin
    Adib, Elio
    Feng, Jamie
    Aredo, Jacqueline V.
    Parikh, Kaushal
    Harris, Jeremy Phillip
    Manana, Ana I. Velazquez
    Ragavan, Meera Vimala
    Lin, Jessica Jiyeong
    Piotrowska, Zofia
    Fitzgerald, Bailey Gleason
    Grohe, Christian
    Sankar, Kamya
    Neal, Joel W.
    Wakelee, Heather A.
    Shepherd, Frances A.
    Herbst, Roy S.
    Naqash, Abdul Rafeh
    Goldberg, Sarah B.
    Kim, So Yeon
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [7] Consolidation ALK Tyrosine Kinase Inhibitors Versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK-Positive NSCLC
    Nassar, Amin H.
    Jayakrishnan, Ritujith
    Feng, Jamie
    Shepherd, Frances
    Adib, Elio
    Cheung, Justin M.
    Lin, Jessica J.
    Liu, Yufei
    Lin, Steven H.
    Parikh, Kaushal
    Sridhar, Arthi
    Shakya, Purnima
    Dilling, Thomas J.
    Kaldas, David
    Gray, Jhanelle E.
    Lobachov, Anastasiya
    Bar, Jair
    Luders, Heike
    Grohe, Christian
    Gupta, Shruti
    Leal, Ticiana
    Fitzgerald, Bailey
    Crowley, Fionnuala
    Fujiwara, Yu
    Marron, Thomas U.
    Wilgucki, Molly
    Reuss, Joshua
    Chen, Luxi
    Sankar, Kamya
    Aredo, Jacqueline, V
    Neal, Joel W.
    Wakelee, Heather A.
    Thummalapalli, Rohit
    Yu, Helena
    Whitaker, Ryan
    Velazquez, Ana
    Ragavan, Meera
    Cortellini, Alessio
    Kwiatkowski, David J.
    Naqash, Abdul Rafeh
    Goldberg, Sarah B.
    Kim, So Yeon
    JOURNAL OF THORACIC ONCOLOGY, 2025, 20 (01) : 109 - 118
  • [8] Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib
    White, Maya N.
    Piper-Vallillo, Andrew J.
    Gardner, Rebecca M.
    Cunanan, Kristen
    Neal, Joel W.
    Das, Millie
    Padda, Sukhmani K.
    Ramchandran, Kavitha
    Chen, Thomas T.
    Sequist, Lecia, V
    Piotrowska, Zofia
    Wakelee, Heather A.
    CLINICAL LUNG CANCER, 2022, 23 (03) : E210 - E221
  • [9] Real-world treatment patterns and clinical outcomes in EGFR-mutant unresectable locally advanced NSCLC (LA-NSCLC): A retrospective multicenter study of 367 patients.
    Bi, Nan
    Wang, Luhua
    Xu, Kunpeng
    Ge, Hong
    Mingyan, E.
    Zhang, Li
    Cao, Jianzhong
    Zhang, Xu
    Xia, Bing
    Zhao, Lujun
    Li, Jiancheng
    Hu, Chen
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [10] Erlotinib versus gefitinib for brain metastases in Asian patients with exon 19 EGFR-mutant lung adenocarcinoma: a retrospective, multicenter study
    Jiang, Ye
    Zhang, Jing
    Huang, Juanjuan
    Xu, Bo
    Li, Ning
    Cao, Lei
    Zhao, Mingdong
    BMC PULMONARY MEDICINE, 2018, 18
12